Suggestions
Steven Ringel
GM @ Tempus | Advisor | Advocate
Professional Background
Steven Ringel is a passionate advocate for patients with rare inherited retinal diseases, driven by personal experience as both a patient and a sibling of a patient. His unique perspective fuels his dedication to empower patients and their families as they navigate the complexities of living with these rare conditions. Currently, he holds a pivotal role at Tempus, where he serves as the leader of the TIME trials business unit. TIME aims to revolutionize the clinical trial landscape by utilizing innovative approaches, including Just-in-Time clinical trial site activation. This groundbreaking strategy not only reduces the costs associated with clinical trials but also expands access to novel experimental therapies for millions of patients who might not otherwise receive such treatments. His work is centered around a mission to transform how new treatments are delivered to those in need, creating a brighter future for patients battling rare diseases.
Steven's previous experience at Sema4 highlights his extensive background in the healthcare and biopharma sectors. His roles ranged from Vice President & General Manager of Biopharma, where he oversaw key initiatives in drug development, to his critical contributions as Senior Director Corporate Development. In these positions, he was instrumental in spearheading strategic initiatives that aligned biopharmaceutical innovations with the evolving needs of patients. His tenure at Sema4 also included vital leadership roles in the Rare Disease division, further solidifying his commitment to addressing the challenges faced by those with uncommon health conditions. Additionally, Steven's strategic insights were honed during his time at Bain & Company, where he served as a Senior Associate Consultant, providing him with a robust foundation in business strategy and development.
Education and Achievements
Steven Ringel graduated cum laude with a Bachelor of Arts (B.A.) in Communication Studies from Vanderbilt University, where he developed strong skills in effective communication and advocacy, which are essential in his current role. His educational background equipped him with the tools needed to articulate the needs of rare patients and to drive forward innovative solutions within the healthcare landscape.
Throughout his career, Steven has built an impressive portfolio of accomplishments. He has not only played a pivotal role in advancing clinical practices but has also worked towards enhancing patient access to critical therapies. His leadership in various capacities at Sema4 demonstrated his ability to navigate complex industry challenges while keeping patient welfare at the forefront of organizational strategies. At Illumina, he contributed to groundbreaking genomic advancements that have revolutionized the way we understand and treat rare diseases.
Achievements
- Empowering Patients: Steven's advocacy efforts concentrate on empowering patients and their families as they face the challenges of rare diseases. His personal journey as a patient advocate positions him uniquely in the field, allowing him to resonate with those he aims to assist.
- Leadership at Tempus: Under his leadership, the TIME trials business unit has been at the forefront of innovative clinical trial methodologies, emphasizing efficiency and accessibility. This role reflects his deep commitment to operational excellence and patient-centered care.
- Strategic Development Expertise: With extensive experience in strategic development, Steven has successfully contributed to numerous projects at Sema4 and Tempus that aim to bridge the gap between cutting-edge science and the practical needs of patients.
- Influential Roles: His progression through various roles in the biopharma sector demonstrates his ability to influence change and drive progress within organizations. From Director of Strategy to Vice President & General Manager positions, Steven's career reflects a robust expertise in connecting patients with the treatments they need.
As a passionate advocate and accomplished leader, Steven Ringel continues to make significant strides in the realms of rare disease research and patient empowerment. His unwavering commitment to changing the landscape of clinical trials ensures that more patients can access innovative treatments, paving the way for a hopeful future in healthcare.
Highlights
